Skip to content
Screener

Pacira BioSciences, Inc. PCRX EV / EBITDA

EV / EBITDA at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
3.7×+1.2×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B-11.9%
Enterprise value$1.29B+6.9%
P/E198.5×—
P/S1.4×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

enterprise value/ebitda=10.3×

Based on the most recent quarter.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871

FAQ

What is Pacira BioSciences, Inc.'s EV / EBITDA?
Pacira BioSciences, Inc. (PCRX) reported EV / EBITDA of 10.3× in Q1 2026.
What is the long-term trend for Pacira BioSciences, Inc.'s EV / EBITDA?
Over 3 years (2020 to 2025), Pacira BioSciences, Inc.'s EV / EBITDA has grown at a -33.4% compound annual growth rate (CAGR), from 42.2× to 12.5×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Pacira BioSciences, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude